Premature Ejaculation Clinical Trial
Official title:
Research and Clinical Value of New Classification for Premature Ejaculation:Multi-Center Research
An observational study on the effect of new classification for premature ejaculation.
Premature ejaculation (PE) is one of the the most common male sexual dysfunctions and it has
negative impacts on people's quality of life. According to the time that PE syndromes come
out, PE is clinically divided to primary PE , which appear from the first sex ,and secondary
PE ,which occurred after a period of normal ejaculation. This method of classification make
little sense for treatment. In 2008, PE was divided into four types: primary PE, secondary
PE, natural variable PE and premature-like ejaculatory dysfunction , and different types of
premature ejaculation have their corresponding treatment. Both method of classification are
based on the subjective feelings of patients, then whether certain objective test can be used
to help diagnosing premature ejaculation? The drug treatment of PE mainly includes local
anesthetics and selective 5- serotonin reuptake inhibitor (SSRI), and the selective penile
dorsal nerve block is the most used surgery. But the efficacy of dapoxetine(a new SSRI for
PE) and local anesthetics is only about 60-70% and 60%, respectively, while the efficacy of
surgery is not exact without a standard surgical indication. We suppose that there may be
different subtypes of the nerve of patients with premature ejaculation may exist in, which
corresponds to a specific treatment.
In previous study, the investigators studied the somatic sensory pathway and autonomic nerve
function of patients with premature ejaculation, and found that they were characterized by
different neural electrophysiological characteristics. About 60% patients with primary PE
show hypersensitivity of penis, and the efficacy of local anesthetics or selective penile
dorsal nerve block for them reached 90%. While SSRI can reduce the excitability of the
sympathetic nervous system in patients with PE, and the effect of this drug on patients with
Sympathetic hyperexcitability is better than those without Sympathetic hyperexcitability.
Thus doctors here have already been dividing patients who only suffer from PE(no other
diseases mentioned in exclusion criteria)into 4 groups according to the results of nerve
electrophysiological examination and give corresponding treatment: 1. Penile sensory
hyperexcitability Group, using local anaesthetics(compound lidocaine cream)to treat; 2.
Sympathetic hyperexcitability Group: using selective serotonin reuptake
inhibitor(SSRI)(Dapoxetine) to treat. 3. Mixed type Group: both Penile sensory
hyperexcitability and Sympathetic hyperexcitability: Combined use of two treatments above. 4.
Other Group: result of nerve electrophysiological examination is normal: this group of
patients will receive further examination to figure out the reason. This pattern of treatment
has been used in clinical practice for years.
In this research, the investigators will systemically observe the result of this
classification and treatment for 12 weeks. Patients will be asked for participating in this
research. The questionnaires(IELT,PEDT,PEP) can be filled in when visited or online about
every 4 weeks. If he refused , he would still receive the classified treatment but not
enrolled in this research. After treatment of 12 weeks, the investigators will measure the
change of IELT, PEDT, PEP, nerve electrophysiological examination and CGIC, then compare the
efficacy of the treatment to that has been reported before. If anyone do not want to continue
the treatment, he could quit from this research. Software SPSS17.0 will be used for data
analysis. The age, height, weight, quantity table, the latency and amplitude of each group
will be expressed by the mean add or subtract standard deviation. Quantitative data
comparison among groups was analyzed by single factor variance analysis (one-way ANOVA and
LSD), comparison of rate using x2 test, comparison of before and after treatment compared
with paired t test. P<0.05 showed statistically significant difference.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02232425 -
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
|
Phase 2 | |
Completed |
NCT01439984 -
Trial of PED-1 in Male Patients With Premature Ejaculation
|
Phase 3 | |
Completed |
NCT01184105 -
A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation
|
Phase 1 | |
Completed |
NCT01203202 -
Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation
|
Phase 2 | |
Completed |
NCT03942367 -
Evaluation of the Safety and Effectiveness of the vPatch Device
|
N/A | |
Recruiting |
NCT06425211 -
Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
|
N/A | |
Completed |
NCT02939495 -
The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy
|
Phase 4 | |
Recruiting |
NCT02581826 -
Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation
|
Phase 2 | |
Terminated |
NCT00983736 -
Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation
|
Phase 3 | |
Completed |
NCT00556478 -
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
|
Phase 2/Phase 3 | |
Completed |
NCT00549211 -
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
|
Phase 1 | |
Not yet recruiting |
NCT05556083 -
Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)
|
Phase 2 | |
Completed |
NCT03304808 -
Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device: Star-Stop 3.0
|
N/A | |
Completed |
NCT00861484 -
Proof of Mechanism in ELT
|
Phase 1 | |
Completed |
NCT02984592 -
Effect of Exercise on Premature Ejaculation
|
N/A | |
Recruiting |
NCT02571101 -
A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation
|
Phase 2 | |
Completed |
NCT03174470 -
Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
|
N/A | |
Completed |
NCT02794454 -
A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health
|
N/A | |
Completed |
NCT02297152 -
A New Treatment for Premature Ejaculation?
|
N/A | |
Not yet recruiting |
NCT00656552 -
Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation
|
Phase 0 |